FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164767134> ?p ?o ?g. }

• W3164767134 endingPage "503" @default.
• W3164767134 startingPage "494" @default.
• W3164767134 abstract "The market for products containing cannabidiol (CBD) is booming globally. However, the pharmacokinetics of CBD in different oral formulations and the impact of CBD use on urine drug testing outcomes for cannabis (e.g., 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (Δ9-THCCOOH)) are understudied. This study characterized the urinary pharmacokinetics of CBD (100 mg) following vaporization or oral administration (including three formulations: gelcap, pharmacy-grade syrup and or Epidiolex) as well as vaporized CBD-dominant cannabis (containing 100 mg CBD and 3.7 mg Δ9-THC) in healthy adults (n = 18). A subset of participants (n = 6) orally administered CBD syrup following overnight fasting (versus low-fat breakfast). Urine specimens were collected before and for 58 h after dosing on a residential research unit. Immunoassay (IA) screening (cutoffs: 20, 50 and 100 ng/mL) for Δ9-THCCOOH was performed, and quantitation of cannabinoids was completed via LC-MS-MS. Urinary CBD concentrations (ng/mL) were higher after oral (mean Cmax: 734; mean Tmax: 4.7 h, n = 18) versus vaporized CBD (mean Cmax: 240; mean Tmax: 1.3 h, n = 18), and oral dose formulation significantly impacted mean Cmax (Epidiolex = 1,274 ng/mL, capsule = 776 ng/mL, syrup = 151 ng/mL, n = 6/group) with little difference in Tmax. Overnight fasting had limited impact on CBD excretion in urine, and there was no evidence of CBD conversion to Δ8- or Δ9-THC in any route or formulation in which pure CBD was administered. Following acute administration of vaporized CBD-dominant cannabis, 3 of 18 participants provided a total of six urine samples in which Δ9-THCCOOH concentrations ≥15 ng/mL. All six specimens screened positive at a 20 ng/mL IA cutoff, and two of six screened positive at a 50 ng/mL cutoff. These data show that absorption/elimination of CBD is impacted by drug formulation, route of administration and gastric contents. Although pure CBD is unlikely to impact drug testing, it is possible that hemp products containing low amounts of Δ9-THC may produce a cannabis-positive urine drug test." @default.
• W3164767134 created "2021-06-07" @default.
• W3164767134 creator A5004834451 @default.
• W3164767134 creator A5024890238 @default.
• W3164767134 creator A5033599789 @default.
• W3164767134 creator A5045373464 @default.
• W3164767134 creator A5049078722 @default.
• W3164767134 creator A5072239291 @default.
• W3164767134 creator A5077953896 @default.
• W3164767134 creator A5086587789 @default.
• W3164767134 creator A5086614747 @default.
• W3164767134 creator A5089636480 @default.
• W3164767134 date "2021-06-18" @default.
• W3164767134 modified "2023-10-06" @default.
• W3164767134 title "Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration" @default.
• W3164767134 cites W1873975405 @default.
• W3164767134 cites W1980269786 @default.
• W3164767134 cites W2089407496 @default.
• W3164767134 cites W2099197644 @default.
• W3164767134 cites W2211460847 @default.
• W3164767134 cites W2340835897 @default.
• W3164767134 cites W2521558311 @default.
• W3164767134 cites W2526044054 @default.
• W3164767134 cites W2613685814 @default.
• W3164767134 cites W2767817531 @default.
• W3164767134 cites W2899486305 @default.
• W3164767134 cites W2910497884 @default.
• W3164767134 cites W2914962560 @default.
• W3164767134 cites W2972614719 @default.
• W3164767134 cites W2978902730 @default.
• W3164767134 cites W2988082958 @default.
• W3164767134 cites W3014341610 @default.
• W3164767134 cites W3021925421 @default.
• W3164767134 cites W3025529273 @default.
• W3164767134 cites W3045132465 @default.
• W3164767134 cites W3095718398 @default.
• W3164767134 doi "https://doi.org/10.1093/jat/bkab059" @default.
• W3164767134 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34089060" @default.
• W3164767134 hasPublicationYear "2021" @default.
• W3164767134 type Work @default.
• W3164767134 sameAs 3164767134 @default.
• W3164767134 citedByCount "14" @default.
• W3164767134 countsByYear W31647671342021 @default.
• W3164767134 countsByYear W31647671342022 @default.
• W3164767134 countsByYear W31647671342023 @default.
• W3164767134 crossrefType "journal-article" @default.
• W3164767134 hasAuthorship W3164767134A5004834451 @default.
• W3164767134 hasAuthorship W3164767134A5024890238 @default.
• W3164767134 hasAuthorship W3164767134A5033599789 @default.
• W3164767134 hasAuthorship W3164767134A5045373464 @default.
• W3164767134 hasAuthorship W3164767134A5049078722 @default.
• W3164767134 hasAuthorship W3164767134A5072239291 @default.
• W3164767134 hasAuthorship W3164767134A5077953896 @default.
• W3164767134 hasAuthorship W3164767134A5086587789 @default.
• W3164767134 hasAuthorship W3164767134A5086614747 @default.
• W3164767134 hasAuthorship W3164767134A5089636480 @default.
• W3164767134 hasBestOaLocation W31647671342 @default.
• W3164767134 hasConcept C112705442 @default.
• W3164767134 hasConcept C118552586 @default.
• W3164767134 hasConcept C126322002 @default.
• W3164767134 hasConcept C170493617 @default.
• W3164767134 hasConcept C185592680 @default.
• W3164767134 hasConcept C22979827 @default.
• W3164767134 hasConcept C2776895053 @default.
• W3164767134 hasConcept C2777056318 @default.
• W3164767134 hasConcept C2777056448 @default.
• W3164767134 hasConcept C2778563155 @default.
• W3164767134 hasConcept C2780026642 @default.
• W3164767134 hasConcept C2780871563 @default.
• W3164767134 hasConcept C2781090866 @default.
• W3164767134 hasConcept C2908858883 @default.
• W3164767134 hasConcept C71924100 @default.
• W3164767134 hasConcept C98274493 @default.
• W3164767134 hasConceptScore W3164767134C112705442 @default.
• W3164767134 hasConceptScore W3164767134C118552586 @default.
• W3164767134 hasConceptScore W3164767134C126322002 @default.
• W3164767134 hasConceptScore W3164767134C170493617 @default.
• W3164767134 hasConceptScore W3164767134C185592680 @default.
• W3164767134 hasConceptScore W3164767134C22979827 @default.
• W3164767134 hasConceptScore W3164767134C2776895053 @default.
• W3164767134 hasConceptScore W3164767134C2777056318 @default.
• W3164767134 hasConceptScore W3164767134C2777056448 @default.
• W3164767134 hasConceptScore W3164767134C2778563155 @default.
• W3164767134 hasConceptScore W3164767134C2780026642 @default.
• W3164767134 hasConceptScore W3164767134C2780871563 @default.
• W3164767134 hasConceptScore W3164767134C2781090866 @default.
• W3164767134 hasConceptScore W3164767134C2908858883 @default.
• W3164767134 hasConceptScore W3164767134C71924100 @default.
• W3164767134 hasConceptScore W3164767134C98274493 @default.
• W3164767134 hasFunder F4320332164 @default.
• W3164767134 hasFunder F4320337347 @default.
• W3164767134 hasIssue "5" @default.
• W3164767134 hasLocation W31647671341 @default.
• W3164767134 hasLocation W31647671342 @default.
• W3164767134 hasLocation W31647671343 @default.
• W3164767134 hasOpenAccess W3164767134 @default.
• W3164767134 hasPrimaryLocation W31647671341 @default.
• W3164767134 hasRelatedWork W1772744802 @default.

• next